• Title/Summary/Keyword: epidermal Growth factor

Search Result 628, Processing Time 0.025 seconds

UV Effect on Plant Growth

  • Kondo, Noriaki;Tou, Seiji;Takahashi, Shinya;Nakajima, Nobuyoshi
    • Journal of Photoscience
    • /
    • v.9 no.2
    • /
    • pp.158-161
    • /
    • 2002
  • UV-B radiation gives harmful effects on plants, such as production of several types of DNA lesions, and growth inhibition. On the other hand, plants have some protective mechanisms, including filtering effect due to accumulation of phenolic compounds in epidermal cells and reactivation of DNA lesions, which are enhanced by UV-B irradiation. We have investigated the mechanism of UV-B effects on plants using cucumber seedlings as plant materials. Cucumber plants were cultivated in an artificially lit growth chamber. Supplemental UV-B irradiation, of which intensity was almost equal to the level of natural sunlight, retarded the growth of first leaves. The growth retardation must result trom the inhibition of cell division and/or cell growth. Microscopical observation of leaf epidermis suggested that the growth retardation might be mainly caused by cell growth inhibition. The retardation was, however, restored within 2 or 3 days after the termination of UV-B irradiation. It is known that UV-B irradiation lowers the activity of photo system II (PS II). In the present experimental conditions, however, UV-B irradiation has little effect on PS II activity as estimated by chlorophyll fluorescence. The stomatal conductance, a major factor determining photosynthetic rate, of first leaves increased during the growth. The increase of stomatal conductance was suppressed by UV-B irradiation and restored by termination of the irradiation. It has not been clear, however, what mechanisms are involved in the suppression of increase of stomatal conductance.

  • PDF

THE EFFECTS OF EGF ON PROLIFERATION AND ATTACHMENT OF HUMAN PERIODONTAL FIBROBLASTS (표피성장인자가 치주인대 섬유 모세포의 증식과 부착에 미치는 영향)

  • Lee, Jong-Eun;Kim, Chong-Kwan;Kim, Seong-Oh;Kim, Yun-Tae;Choi, Hyung-Jun
    • Journal of the korean academy of Pediatric Dentistry
    • /
    • v.32 no.3
    • /
    • pp.395-402
    • /
    • 2005
  • In considering the healing process of injured periodontal tissue, healing rate would be influenced by the cellular activity of periodontal fibroblasts(PDLFs). In addition, the reattachment among PDLFs should be induced for healing process. The purpose of this study was to evaluate the effects of epidermal growth factor(EGF) on the proliferation and attachment of PDLFs and to verify the efficacy of EGF as a storage media or a pre-replantation conditioner of traumatically avulsed tooth. Human recombinant epidermal growth factor(hrEGF) and human periodontal fibroblasts from first premolar were prepared. At first, MTT assay was done to evaluate the toxic effect on human periodontal fibroblast and the maximum cellular growth of EGF. Cellular proliferation rate was then compared between control group and 10ng/ml EGF added group. Also, western blot was done to evaluate the expression of fibronectin in both groups. The results were as follows: 1. From MTT assay, EGF showed no toxic effect on PDL fibroblasts. The highest proliferation was shown at 10ng/ml EGF. 2. In 10ng/ml EGF added group, the degree of proliferation of PDLFs was significantly higher than that in control group. 3. Fibronectin expression of EGF added group was also significantly higher than that of control group. From this study we could conclude that EGF enhanced the regeneration rate of periodontal fibroblast, which could be used as a pretreatment agent or a storage media for traumatically avulsed teeth.

  • PDF

Synergistic Inhibition of Burkitt's Lymphoma with Combined Ibrutinib and Lapatinib Treatment (Ibrutinib과 Lapatinib 병용 치료에 의한 버킷림프종의 상호 작용적 억제)

  • Chae-Eun YANG;Se Been KIM;Yurim JEONG;Jung-Yeon LIM
    • Korean Journal of Clinical Laboratory Science
    • /
    • v.55 no.4
    • /
    • pp.298-305
    • /
    • 2023
  • Burkitt's lymphoma is a distinct subtype of non-Hodgkin's lymphoma originating from B-cells that is notorious for its aggressive growth and association with immune system impairments, potentially resulting in rapid and fatal outcomes if not addressed promptly. Optimizing the use of Food and Drug Administration-approved medications, such as combining known safe drugs, can lead to time and cost savings. This method holds promise in accelerating the progress of novel treatments, ultimately facilitating swifter access for patients. This study explores the potential of a dual-targeted therapeutic strategy, combining the bruton tyrosine kinase-targeting drug Ibrutinib and the epidermal growth factor receptor/human epidermal growth factor receptor-2-targeting drug Lapatinib. Ramos and Daudi cell lines, well-established models of Burkitt's lymphoma, were used to examine the impact of this combination therapy. The combination of Ibrutinib and Lapatinib inhibited cell proliferation more than using each drug individually. A combination treatment induced apoptosis and caused cell cycle arrest at the S and G2/M phases. This approach is multifaceted in its benefits. It enhances the efficiency of the drug development timeline and maximizes the utility of currently available resources, ensuring a more streamlined and resource-effective research process.

Experimental Study on the Expression of Hair Growth Related Factors after Bee Venom Acupuncture Therapy (봉독약침요법(蜂毒藥鍼療法)에 의한 발모관련 인자들의 발현에 대한 연구)

  • Kim, Ho-Il;Kim, Cheong-Moo;Shin, Hyun-Jong;Lee, Chang-Hyun
    • Journal of Physiology & Pathology in Korean Medicine
    • /
    • v.25 no.3
    • /
    • pp.496-502
    • /
    • 2011
  • The present study was undertaken to investigate the effect of bee venom acupuncture therapy on the hair follicle growth by macroscopic, microscopic and immunohistochemical observation of skin 10 and 17 days after treatment. The results were as follows : Macroscopic hair follicle growth of 0.2 ml S.B.V. acupuncture treated group was more prominent than those of 0.1 ml S.B.V. acupuncture treated group and control group. Microscopic observation indicated that the hair follicle growth of control group reached anagen phase IV of hair growing cycle, and that of 0.1 ml and 0.2 ml S.B.V. acupuncture treated groups reached anagen phase VI and catagen, respectively. Immunohistochemical observations of the expression of various cytokines, enzymes and receptors in association with hair follicle cycle after local treatment of S.B.V. acupuncture therapy are as follows: Expression of fibroblast growth factor was more intense in epidermis and outer root sheath in 0.2 ml S.B.V. acupuncture treated group than that of 0.1 ml S.B.V. acupuncture treated group and control group. Expression of epidermal growth factor was more intense in bulge and outer root sheath in 0.2 ml S.B.V. acupuncture treated group than that of 0.1 ml S.B.V. acupuncture treated group and control group. Expression of c-kit receptor was more intense in epidermis, bulge and outer root sheath in 0.2 ml S.B.V. acupuncture treated group than that of control group. Expression of vascular endothelial growth factor was more intense in epidermis, bulge and outer root sheath in 0.2 ml S.B.V. acupuncture treated group than that of control group. Expression of protein kinase C-${\alpha}$ was more intense in epidermis, bulge and outer root sheath in 0.2 ml S.B.V. acupuncture treated group than control group. It is concluded that bee venom acupuncture therapy promoted the expression of various cytokines, enzymes and receptors related to the hair growth cycle for hair growth. This findings indicates that bee venom acupuncture therapy is applicable to the treatment of hair loss.

Roles of Immunohistochemical Staining in Diagnosing Pulmonary Squamous Cell Carcinoma

  • Yan, Yue;Zhang, Ya-Xiong;Fang, Wen-Feng;Kang, Shi-Yang;Zhan, Jian-Hua;Chen, Nan;Hong, Shao-Dong;Liang, Wen-Hua;Tang, Yan-Na;He, Da-Cheng;Wu, Xuan;Zhang, Li
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.2
    • /
    • pp.551-557
    • /
    • 2015
  • Background: Differentiating morphologic features based on hematoxylin-eosin (HE) staining is the most common method to classify pathological subtypes of non-small-cell lung cancer (NSCLC). However, its accuracy and inter-observer reproducibility in pathological diagnosis of poorly differentiated NSCLC remained to be improved. Materials and Methods: We attempted to explore the role of immunohistochemistry (IHC) staining in diagnosing pulmonary squamous cell carcinoma (SQCC) with poorly differentiated features by HE staining or with elevated serum adenocarcinoma-specific tumor markers (AD-TMs). We also compared the difference of epidermal growth factor receptor (EGFR) mutation rate between patients with confirmed SQCC and those with revised pathological subtype. Logistic regression analyses were used to test the association between different factors and diagnostic accuracy. Results: A total of 132 patients who met the eligible criteria and had adequate specimens for IHC confirmation were included. Pathological revised cases in poor differentiated subgroup, biopsy samples and high-level AD-TMs cases were more than those with high/moderate differentiation, surgical specimens and normal-level AD-TMs. Moreover, biopsy sample was a significant factor decreasing diagnostic accuracy of pathological subtype (OR, 4.037; 95% CI 1.446-11.267, p=0.008). Additionally, EGFR mutation rate was higher in patients with pathological diagnostic changes than those with confirmed SQCC (16.7% vs 4.4%, p=0.157). Conclusions: Diagnosis based on HE staining only might cause pathological misinterpretation in NSCLC patients with poor differentiation or high-level AD-TMs, especially those with biopsy samples. HE staining and IHC should be combined as pathological diagnostic standard. The occurrence of EGFR mutations in pulmonary SQCC might be overestimated.

${\gamma}$-NGF Produced in CHO Cells Does Not Cleave Mouse Ren-2 Prorenin

  • Rhee, Hee-Sub;Jeon, Byung-Hoon;Kim, Won-Sin
    • Animal cells and systems
    • /
    • v.1 no.3
    • /
    • pp.463-466
    • /
    • 1997
  • We have recently demonstrated, by protein and cDNA sequence analysis, that prorenin converting enzyme (PRECE) in the mouse submandibular gland is identical to the epidermal growth factor-binding protein (EGF-BP)type B. However, type A and C did not show prorenin converting activity. To demonstrate whether r-NGF is involved in prorenin processing, we have cloned cDNA of r-NGF and examined prorenin converting activity using the CHO cell expression system, Trypsin converted the 33 kDa r-NGF precursor produced in CHO cells to a two-chain form, 9.4 and 16.4 kDa polypeptide chains, which has been known as an active form of r-NGF in mouse SMG (Server and Shooter, 1976). However, the two chain forms of r-NGF did not reveal prorenin-processing activity. Thus, only PRECE is involved in prorenin processing in mouse SMG. This result shows that their substrate specificities appear to be very strict, although some kallikreins share a high degree of amino acid sequence identity.

  • PDF

What is the Mechanism of Progression with Trastuzumab Treatment - Escape or Resistance?

  • Sendur, Mehmet Ali Nahit;Aksoy, Sercan;Ozdemir, Nuriye Yildirim;Zengin, Nurullah;Altundag, Kadri
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.11
    • /
    • pp.5915-5916
    • /
    • 2012
  • Human epidermal growth factor receptor (HER) 2 overexpression, observed in 20-25 percent of invasive breast cancers, is well known to be associated with a more aggressive phenotype and poor prognosis, with resistance to certain chemotherapeutic agents. The majority of patients with metastatic breast cancer who initially respond to trastuzumab, demonstrate disease progression within 1 year of treatment initiation. Furthermore, lack of response in some patients and relapse during the course of therapy, continue to challenge researchers and clinicians. A better understanding of the fundamental mechanisms of trastuzumab action is required so that new therapies directed at HER2 can be developed. We present here findings for mechanisms, both of Trastuzumab action and clinical resistance or escape.

A Phase II, double-blinded, randomized, multicenter clinical trial for evaluation of efficacy and safety of rhEGF in patients with diabetic foot ulcer (제 2 상, 이중맹검, 무작위배정, 다기관 공동임상시험의 결과 : 당뇨병성 족부궤양에 대한 표피 성장인자(Epidermal Growth Factor, EGF)의 치료 효과를 평가)

  • Choi Ji-Hyeon;Jung Kui-Oak;Sohn Ho-Young;Kim Young-Sul;Lee Hong-Gyu;Lee Kui-Up;Lee Hyun-Chul;Lee Byung-Doo;Park Byung-Joo
    • 대한예방의학회:학술대회논문집
    • /
    • 2001.10a
    • /
    • pp.305-307
    • /
    • 2001
  • PDF

Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer

  • Choi, Mihong;Lee, Youngjoo;Hwang, Sang Hyun;Lee, Jin Soo
    • Tuberculosis and Respiratory Diseases
    • /
    • v.77 no.6
    • /
    • pp.271-273
    • /
    • 2014
  • Disease flare-up after discontinuing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been considered as a critical issue in lung cancer patients who have experienced radiologic progression after showing initial durable response. This is a case of systemic nocardiosis that occurred after chronic steroid use for radionecrosis from stereotactic radiosurgery. It was initially thought as a disease flare-up after stopping EGFR-TKI.

Current Status of Immunotherapy for Lung Cancer and Future Perspectives

  • Kim, Ho Cheol;Choi, Chang-Min
    • Tuberculosis and Respiratory Diseases
    • /
    • v.83 no.1
    • /
    • pp.14-19
    • /
    • 2020
  • Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors, new therapeutic strategies are needed to improve clinical outcomes. Immunotherapy through the use of immune checkpoint inhibitors has provided one of the most important breakthroughs in the management of solid tumors, including lung cancers, and has shown promising results in numerous clinical trials. This review will present the current status of immunotherapy for lung cancer and future perspectives on these treatments.